Skip to main content

Health economic modeling for medical technologies in Europe

Early and comprehensive economic models to determine economic value proposition and inform healthcare decision-makers

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Intra-DRG list updated in France

Certain medical devices are financed within the DRG tariff but require explicit review of clinical evidence by the National Commission for the Evaluation of Medical Devices and Health Technologies CNEDiMTS to ensure that they are safe and effective. This mechanism is called “intra-DRG (intra-GHS) coverage”. The mechanism is applicable to particularly invasive devices. Only devices listed in the intra-DRG list can be purchased by hospitals.

In the middle of March 2023, the updated version of the intra-DRG list was published. Changes include the introduction of several devices for thrombo-aspiration into the list and the deletion of a few devices from the list.

Examples of the included thrombo-aspiration devices:

  • Distal access catheters used in REACT thrombo-aspiration systems from MEDTRONIC;
  • Thrombo-aspiration systems PENUMBRA ACE 60, PENUMBRA ACE 68, PENUMBRA 3MAXC, PENUMBRA JET 7, PENUMBRA JET D from PENUMBRA.

More details can be found in French here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Contact us to get a free, three-month, no-obligation trial.